Last reviewed · How we verify
NCT07260461
The Efficacy and Safety of Laparoscopic Proximal Gastrectomy With LPG-tbROSF Versus LTG for Localized Proximal Gastric Cancer.
NA trial testing Laparoscopic Proximal Gastrectomy with Tubular Stomach-Based Right-Opening Single Flap Valvuloplasty (LPG-tbROSF) in Stomach Neoplasms in 120 participants. Not yet recruiting.
1 September 2027
Quick facts
| Lead sponsor | First Affiliated Hospital of Wenzhou Medical University |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 1 January 2026 |
| Primary completion | 1 September 2027 |
| Estimated completion | 1 September 2028 |
Drugs / interventions tested
- Laparoscopic Proximal Gastrectomy with Tubular Stomach-Based Right-Opening Single Flap Valvuloplasty (LPG-tbROSF)
Conditions studied
- Stomach Neoplasms — all drugs for Stomach Neoplasms →
- Adenocarcinoma - Gastroesophageal Junction (GEJ) — all drugs for Adenocarcinoma - Gastroesophageal Junction (GEJ) →
- Gastroesophageal Junction Cancer — all drugs for Gastroesophageal Junction Cancer →
Sponsor
First Affiliated Hospital of Wenzhou Medical University
Who can join
Adults 15 to 75, any sex, with Stomach Neoplasms or Adenocarcinoma - Gastroesophageal Junction (GEJ). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical trial is evaluating a new, function-preserving surgical technique for patients with early-stage cancer in the upper part of the stomach. The current standard treatment is a Laparoscopic Total Gastrectomy (LTG), which involves the complete removal of the stomach. This study compares the standard LTG with an innovative procedure called Laparoscopic Proximal Gastrectomy combined with a novel anti-reflux reconstruction (LPG-tbROSF). This new technique removes only the cancerous upper portion of the stomach, aiming to preserve digestive functions and reduce post-surgery complications like acid reflux. The main goal is to see if patients who receive the new, stomach-preserving surgery experience less body weight loss one year after the procedure compared to those who undergo the standard total gastrectomy. The research will also compare the two surgeries in terms of post-operative quality of life, nutritional status, acid reflux symptoms, safety, and long-term cancer outcomes. The study is a multi-center, prospective, randomized controlled trial that plans to enroll 120 patients with localized cancer in the upper stomach.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07260461
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Stomach Neoplasms
Currently open trials in the same condition.
- NCT07482566 — Proximal Versus Total Gastrectomy for Locally Advanced Siewert Type II-III Gastroesophageal Junction Cancer · NA · recruiting
- NCT06885697 — Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Includi · Phase 1 · recruiting
- NCT07504913 — Spanish Validation of KOQUSS-40 Questionnaire: Assessing QoL of Gastric Cancer Patients After Gastrectomy: SPQUSS-41 · recruiting
- NCT07113340 — Carina™ Surgical Platform for Minimal Radical Gastrectomy · NA · active not recruiting
- NCT06630130 — Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer · Phase 2 · recruiting
Other First Affiliated Hospital of Wenzhou Medical University trials
Trials by the same sponsor.
- NCT07394205 — Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Can · EARLY_PHASE1 · not yet recruiting
- NCT07179120 — Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm · Phase 2 · not yet recruiting
- NCT07495735 — Intelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellula · not yet recruiting
- NCT07381634 — The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities · Phase 2 · not yet recruiting
- NCT07284524 — Intelligent Precision Knee Preservation System for Knee Osteoarthritis · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07260461 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Wenzhou Medical University
- Last refreshed: 3 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07260461.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing